Navigation Links
Oncothyreon reports first quarter 2010 financial results
Date:5/6/2010

SEATTLE, WA, May 6 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) (the "Company") today reported a net loss of $0.8 million or $0.03 per basic and diluted share for the quarter ended March 31, 2010, compared with a net loss of $2.5 million or $0.13 per basic and diluted share for the comparable period in 2009. The decrease in net loss is primarily the result of a decrease in fair value of warrant liability of $4.6 million, offset by an increase in net loss from operations.

Net loss from operations increased to $5.4 million in the first quarter of 2010 from $2.5 million in the first quarter of 2009, primarily as the result of increased research and development and general and administrative expenses. Research and development expenses increased to $2.5 million from $0.7 million, reflecting increased development activity for the Company's product candidates PX-866 and ONT-10. General and administrative expenses increased to $2.8 million from $1.8 million, primarily as the result of legal and consulting expenses related to regulatory compliance.

As of March 31, 2010, Oncothyreon's cash, cash equivalents and short term investments were $28.8 million, compared to $33.2 million at the end of 2008, a decrease of $4.4 million, or 13.3 percent, a
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
2. Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement
3. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
4. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
5. Oncothyreon announces webcast of third quarter 2009 financial results conference call
6. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
7. Oncothyreon to present at Rodman Renshaw Global Healthcare Conference
8. Oncothyreon reports second quarter 2009 financial results
9. Oncothyreon announces closing of $15.0 million registered direct financing
10. Oncothyreon announces webcast of second quarter 2009 financial results conference call
11. Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... HUYA Bioscience International (HUYA) today announced the sponsorship ... of HTLV-1, held this week at the University of ... Society is to promote research on HTLV-1 and HTLV-1-associated ... and research related to these fields to advance science, ... proud to support this prestigious conference," said Mireille ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... and expertly narrows down the product choices to a manageable shortlist of bench ... the list to models that fit best with the customer’s industry and application. ...
(Date:8/26/2015)... ... 2015 , ... MediVet Biologics, a leader in Veterinary Regenerative ... open in Manhattan, Kansas in early October, 2015. The location of the lab ... development through collaboration with researchers from Kansas State University’s College of Veterinary Medicine. ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, ... the development and manufacture of highly valued cardiac markers used in early detection ... expertise with protein chemistry has led to the development and commercialization of important ...
Breaking Biology Technology:HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4METTLER TOLEDO Updates Online Scale Selection Tool 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2
... December - - PC-Insulin Preclinical Study Results ... Biotechnologies,Inc. (TSX:CJB) announced today that dosing is complete ... Phase II trial was a,randomized, double-blind, placebo-controlled, multiple ... three months of weekly injections of,PC-DAC(TM):Exendin-4 in patients ...
... NOVATO, Calif., Nov. 5 BioMarin,Pharmaceutical Inc. (Nasdaq: ... of BioMarin, will present a company,update at the Credit ... November 12, 2008 at 10:30 a.m. MST., Interested ... conference,call via the investor section of the BioMarin website, ...
... DIEGO, Nov. 5 Ambrx Inc. today announced ... clinical trial of ARX201,the company,s long-acting human growth ... at the International Congress of,Endocrinology meeting in Rio ... and Vice President of Academic Affairs at Stanford ...
Cached Biology Technology:ConjuChem Provides Development Update 2ConjuChem Provides Development Update 3BioMarin to Present at the Credit Suisse Healthcare Conference 2Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue 2
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/3/2015)... 3, 2015 Synaptics, Inc. (Nasdaq: SYNA ... announced that members of the executive management team will ... Global Technology Leadership Forum on Tuesday, August 11, 2015 ... held at the Sonnenalp Resort in Vail, ... include forward-looking information. An audio webcast of the event ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... Highlights from the Lymphoma Research Foundation (LRF) 2009 Mantle Cell ... the March 2010 issue of Leukemia & Lymphoma. Traditionally ... Lymphoma has agreed to make this report available to the ... of the 2009 MCL Consortium Workshop. "It is gratifying ...
... Resistant wheat plants stave off attacks by Hessian fly larvae ... absorb nutrients, according to a study by Purdue University and ... - similar to human intestines - were observed in three ... function. Those that were given nothing to eat showed no ...
... Allergies and Infectious Diseases (NIAID), part of the National ... totaling $15,254,919 to Tulane University for its ongoing efforts ... viral disease that threatens hundreds of thousands of people ... potential bioterrorism threat. The contract will include collaboration ...
Cached Biology News:Resistant wheat goes for the gut to protect against Hessian flies 2Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever 2
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
ANTI S. ENTERID LPS...
... ELISA Development kit contains the basic components ... to measure natural and recombinant Feline IL-10 ... kit contains sufficient materials to run ELISAs ... the following conditions are met: The ...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant rat ... Each kit contains sufficient materials to ... provided that the following conditions are met: ...
Biology Products: